Apogenix GmbH
- Biotech or pharma, therapeutic R&D
We are a clinical stage, single asset company. Our drug asset asunercept/APG101 is a Fc fusion protein that is ready for phase II in lower risk myelodysplastic syndromes (MDS) and has already achieved proof-of-concept in MDS (phase I/II), rGBM (phase II) and COVID-19 (phase III stopped). 20.000 doses in stock to start the phase II upon funding.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}